Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

With the advent of novel cancer therapeutics and improved screening, more patients are
surviving a cancer diagnosis or living longer with advanced disease. Many of these …

Cardiotoxicity, the often-overlooked second leading cause of death in cancer patients, has
been associated with certain anticancer drugs. These drugs can induce cardiac damage …

Various ECG changes and arrhythmias can be seen even during the first infusion of
anthracyclines. They are usually nonspecific and include ST-T segment changes, QRS …

Significant advances in cancer treatment have resulted in decreased cancer related
mortality for many malignancies with some cancer types now considered chronic diseases …

Cardiovascular toxicity is a potential complication of cancer chemotherapy (CC) that
increases the morbidity and mortality of cancer patients. Cardiac arrhythmias have been …

The nitrogen mustards are powerful cytotoxic and lymphoablative agents and have been
used for more than 60 years. They are employed in the treatment of cancers, sarcomas, and …

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological
cancers. It predominantly affects elderly people; median age at diagnosis is 70 years …

With the continuous improvement in survival of cancer patients, including those with multiple
myeloma, related to the novel treatment agents and therapeutic approaches, the probability …

Several anticancer agents have been associated with cardiac toxic effects. The currently
proposed mechanisms to explain cardiotoxicity differ among anticancer agents, but in fact …